April Fools!
It turns out it is me for purcha$ing a Boston Globe today, and you will soon see why above in the selections I will be giving you today.
Picking up where we left off and began:
"Anita Hill steps back into the spotlight in documentary" by Joseph P. Kahn | Globe Staff April 01, 2014
NEW YORK — “Anita” represents a coming out of sorts for Hill, who has been largely out of the public eye since becoming a Brandeis University professor 16 years ago. But it is also, by design, a vehicle for Hill to share her views on racial and gender inequality with members of a younger generation for whom the Senate hearings are ancient history.
In October 1991, Hill’s testimony on live television riveted the nation and sparked a passionate debate about sexual harassment in the workplace and elsewhere. It threatened the confirmation of a Supreme Court nominee, embarrassed an all-white male Senate committee seeking to challenge her credibility, and helped spur congressional action allowing victims of sex discrimination to seek federal damage awards.
Embarrassed senatorial scum that were the worst violators -- but champions of women rights so it was all allowed to pass.
At the Manhattan theater last month, a polished, poised Hill, now 57, answered questions from the audience about the historic hearings. No, she’s not bitter, she said, and, yes, the harassment problem is still with us, underscored by recent news stories about sexual assaults in the military and on college campuses.
Related: U.S. Military Making Their Move
Liberating women from their oppressors worldwide, even if we have to murder thousands of them to do it!
“It’s time to start that conversation again,” Hill said forcefully, “to move us to the next level.” Clearly, she added, waiting for elected officials to act is not enough.
Just in time for the election campaign season, great.
The documentary, which opens in the Boston area on Friday, may help jump-start that conversation....
No offense, but I guess I'm too old because I'm finding all this stuff tawdry.
--more--"
I know, I know, I need to relax.....
"Court rejects new cases on birth control coverage" Associated Press April 01, 2014
WASHINGTON — The Supreme Court refused to overturn Arizona court rulings ordering the Yuma County sheriff to return marijuana that was seized from a woman with a California medical marijuana authorization honored by Arizona.
Even a blind squirrel finds an acorn.
The justices’ order was issued without comment in the case of Valerie Okun, who had marijuana in her car when a Border Patrol agent stopped her and her husband in Yuma County, Ariz., in 2011.
She was charged with marijuana possession crimes, but the charges were dropped when she provided proof she was authorized to possess marijuana under California’s medical marijuana program.
Arizona’s medical marijuana law allows people with authorizations from other states to have marijuana in Arizona.
But the Yuma County sheriff refused to return Okun’s marijuana, even after Arizona courts ruled in her favor.
(Blog editor just shakes his head at authority's arrogance. They are above the law!)
In a separate matter Monday....
Oh, yeah, the contraceptive thing.
--more--"
Related: Alabama abortion law challenge must go to trial, judge rules
Time to abort this post:
"High court considers software patent limits" by Sam Hananel | Associated Press April 01, 2014
WASHINGTON — The Supreme Court heard arguments Monday on whether the government should raise the threshold for issuing patents for computer software.
The central issue before the justices was whether it is too easy for high-tech companies to patent inventions that are not really new, but simply take an old idea and blend it with computer wizardry. The case’s outcome could send tremors through an industry that touches virtually every sector of the economy, from gadgets on smartphones to advances in antilock brakes.
The issue has divided the nation’s technology giants, with such companies as Microsoft Corp. warning that new restrictions could nullify thousands of existing patents that are the product of billions of dollars in research and development. On the other side, firms including Google and Netflix say the free flow of software patents has become a ‘‘plague,’’ blocking innovation.
The justices weighed arguments in a case involving Alice Corp., an Australian company that in the 1990s patented a computer program to reduce the risk in financial transactions. The software allows a neutral third party to make sure all parties to a trade have lived up to their obligations.
Oh, we can't have software programs overlooking and keeping an eye on criminal banks and their market-rigging trades!
New York-based CLS Bank International challenged the patent as invalid, arguing Alice merely took a concept that has been around since ancient human history and programmed it to run through a computer.
They must mean charging u$urious intere$t for loans.
Some justices expressed skepticism over the patent. Justice Anthony Kennedy suggested a bunch of second-year engineering students could come up with the same software over a weekend.
--more--"
"Supreme Court to Hear Appeal of Multiple Sclerosis Drug Case" New York Times April 01, 2014
NEW YORK — The Supreme Court on Monday agreed to hear an appeal from Teva Pharmaceutical Industries, a decision that could conceivably delay generic competition to Teva’s big-selling multiple sclerosis drug Copaxone.
Interesting on who they agree to hear, huh?
An appeals court last July had invalidated a patent that would have protected Copaxone until September 2015. Without that protection, the drug could face competition from lower-priced copies as early as two months from now.
While Teva, an Israeli company, is the world’s largest manufacturer of generic drugs, the branded product Copaxone accounts for about 20 percent of its revenue and around half of its profit. Sales of Copaxone reached $4.3 billion last year, of which $3.2 billion came from the United States.
But health insurers are eagerly anticipating the introduction of a generic. There are none available right now as treatments for multiple sclerosis. And the prices of Copaxone and some of its competitors have roughly quadrupled in the last decade.
Looks like price-gouging for profit to me.
--more--"
I think we can $ee where the ju$tices will be leaning on tho$e ca$es.
And you think I'm being extreme when I note money and Zionist influence on this government?
